Elsevier

Human Pathology

Volume 30, Issue 12, December 1999, Pages 1503-1507
Human Pathology

Original contribution
Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy

https://doi.org/10.1016/S0046-8177(99)90174-0Get rights and content

Abstract

The presence and morphology of high-grade prostatic intra-epithelial neoplasia (H-PIN) was blindly evaluated in 40 totally embedded radical prostatectomy specimens of patients with prostate cancer randomized to either a 3 (n = 18) or 6 months (n = 22) combined androgen blockade regimen before surgery. In 5 cases, neo-adjuvant therapy was abrogated some time before surgery. In the remaining cases, loci of H-PIN were identified in 72% and 59% of prostates from patients treated for 3 and 6 months, respectively. Cellular features used to distinguish H-PIN from normal glands were increased nuclear size, nuclear crowding, anisonucleosis, and disordered nuclear arrangement. In some cases, density of cytoplasm was an additional feature. Unfortunately, the molecular marker erbB2 proved unhelpful for identification of H-PIN. The median number of prostatic glands involved by H-PIN was 19 ± 21 (SD) glands in 3 months treated prostatectomies (n = 18) and 7 ± 12 (SD) glands in 6 months treated prostatectomies (n = 17), a nonsignificant difference (P = .17). H-PIN was localized within areas of residual carcinoma in 62% and 20%, respectively of prostatectomies of patients treated for 3 and 6 months, respectively. Architectural patterns of H-PIN differed at 3 and 6 months of endocrine pretreatment: The predominant tufted pattern at 3 months was replaced by fiat H-PIN at 6 months. The continued expression of androgen receptors and the cell cycle marker MIB-1 in persistent H-PIN suggests that recovery of androgen levels after cessation of androgen blockade therapy will lead to its further expansion.

References (16)

There are more references available in the full text version of this article.

Cited by (0)

1

Prof. F. Labrie holds as co-inventor a patent on combined endocrine therapy of prostate cancer.

View full text